Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Hits New 12-Month High – Should You Buy?

Shares of Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $11.34 and last traded at $11.04, with a volume of 134744 shares trading hands. The stock had previously closed at $10.97.

Wall Street Analyst Weigh In

Separately, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. KGaA in a research note on Monday, February 3rd.

Fresenius SE & Co. KGaA Stock Performance

The business has a fifty day moving average of $10.39 and a 200 day moving average of $9.54. The company has a quick ratio of 1.05, a current ratio of 1.36 and a debt-to-equity ratio of 0.57. The company has a market cap of $24.66 billion, a P/E ratio of 52.57 and a beta of 0.86.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last issued its earnings results on Wednesday, February 26th. The company reported $0.18 earnings per share for the quarter. The business had revenue of $6.01 billion during the quarter. On average, equities analysts predict that Fresenius SE & Co. KGaA will post 0.79 EPS for the current year.

About Fresenius SE & Co. KGaA

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.